Avutometinib and Defactinib: RAMP 201 Clinical Trial Results
I am proud to have led the global RAMP201 trial team which contributed to the FDA accelerated approval in KRAS-mutated recurrent low grade serous ovarian cancer. I am so pleased that this oral drug combination has worked well in women with LGSOC who are in urgent need of new treatments. This is the first approved […]
LGSOC Webinar with Dr Amanda Fader
Dr Amanda Fader is a gynaecological oncologist at Johns Hopkins and the Principal Investigator of theNRG-GY019 clinical trial that could change treatment recommendations for women newly diagnosed with LGSOC Dr Fader presented this informative talk on LGSOC Awareness Day. She generously shared her expertise covering an overview of LGSOC, treatments, clinical trials and new developments […]
Managing Hot Flashes And Joint Pain
Authors: Dr Katelyn Tondo-Steele and Associate Professor Karen McLean. Dr Katelyn Tondo-Steele, DO is based at the University of Michigan. Associate Professor Karen McLean, MD, PhD is a gynaecological oncologist at Roswell Park. In 2020 Associate Professor McLean co-authored a study investigating aromotaste inhibitor use, side effects and discontinuation in gynaecological oncology patients. Hot flashes […]
STAAR Conference: Navigating LGSOC Recurrence–Insights and Strategies
Associate Professor Lauren Cobb from the University of Texas MD Anderson Cancer Center discusses low-grade serous ovarian cancer recurrence including monitoring for recurrence, strategies for living with fear of recurrence, and what someone with recurrence can expect including an overview of different treatment options and the evidence for these. This presentation was given as part […]
STAAR Conference: Towards a Deep Molecular Understanding of Low-Grade Serous Ovarian Cancer
In this video, Professor Kwong-Kwong Wong, a LGSOC scientist from the University of Texas MD Anderson Cancer Center gives a deep dive into the biology and genetics of LGSOC. This presentation was given as part of our American research partner STAAR‘s LGSOC Patient Conference in Houston, Texas in February 2025. https://youtu.be/I4h3xVronq8?si=Jb1sR0aClc2xJWzi Visit STAAR Low-Grade Serous […]
STAAR Conference: What we use and why we use it: Understanding treatment options for LGSOC
How do treatments become recognised, and recommended in low-grade serous ovarian cancer? Dr Brian Slomovitz from Mount Sinai Medical Center in Miami discusses the process for identifying and validating treatments in low-grade serous ovarian cancer, including the role of drug repurposing and how treatments become approved by drug regulation bodies like the FDA. This presentation […]
STAAR Conference: The State of LGSOC: 40+ years of personal observations
Dr David Gershenson is widely recognised as the foremost expert in low-grade serous ovarian cancer. In this presentation delivered at our American research partner STAAR‘s LGSOC Patient Conference in February 2025, he shares the progress low-grade serous ovarian cancer has made, from it’s discovery as a unique cancer, to the first clinical trial, to future […]
STAAR Conference: Clinical trials for low-grade serous ovarian cancer
Watch Professor Rachel Grisham from Memorial Sloan Kettering Cancer Center in the United States, give an update on clinical trials in low-grade serous ovarian cancer. This presentation was given as part of our American research partner STAAR‘s LGSOC Patient Conference in Houston, Texas in February 2025. https://youtu.be/ta6nvuq9WyY?si=3RsueAV1iTDgVj3d Visit STAAR Low-Grade Serous Ovarian Cancer Foundation’s video […]
Update on Chemotherapy Response in Low-Grade Serous Ovarian Cancer
A new study led by Dr. Rachel Grisham and Dr. Beryl Manning-Geist (pictured) from Memorial Sloan Kettering Cancer Center has found that while response rates to chemotherapy are lower than high-grade serous subtypes, this treatment remains an important tool for patients. LGSOC is known to be relatively resistant to chemotherapy, especially before surgery (neo-adjuvant) and […]
LGSOC Webinar With Dr Gershenson
World-renowned low-grade serous ovarian cancer expert Dr David Gershenson, Professor of Gynaecological Oncology and former Department Chair at the University of Texas MD Anderson Cancer Center, delivers an exceptional webinar. In this insightful session, Dr. Gershenson covers key topics related to LGSOC, including diagnosis, current treatment options, and the latest research advancements. https://youtu.be/OmuXjXT6uKk